Analysts on GHDX / Piper reiterates overweight rating
Piper Jaffray reaffirmed their overweight rating on shares of Genomic Health (NASDAQ: GHDX) in a research note
Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of Genomic
Health from an outperform rating to a neutral rating in a research note to investors on Friday, August 17th. They now have a $38.00 price target on the stock.
Separately, analysts at Bank of America initiated coverage on shares of Genomic Health in a research note to investors on Thursday, August 16th. They set a buy rating and a $44.00 price
target on the stock.
Genomic Health last released its earnings data on Wednesday, August 8th. The company reported $0.06 EPS for thequarter, beating the Thomson Reuters consensus estimate of ($0.02) by $0.08. The company’s revenue for the quarterwas up 13.4% on a year-over-year basis.
Genomic Health, Inc. (Genomic Health) is a molecular diagnostics company focused on the development and global commercialization of genomic-based clinical laboratory services , which analyzes the underlying biology of cancer,allowing physicians and patients to make individualized treatment decisions
Analysts at Credit Suisse initiated coverage on shares of Genomic Health (NASDAQ: GHDX) in a research report issued to clients and investors on Monday. The firm set an “outperform” rating and a $43.00 price target on the stock.